Document:

PURCHASE AND SALE AGREEMENT

          THIS
PURCHASE AND SALE AGREEMENT (the “Agreement”) is made this 2nd day
of September, 2009, by and between JORNIK, INC., a California corporation,
hereinafter (“Seller”) and ES RX, INC., a California corporation, hereinafter
(“Buyer”).

RECITALS

          A.          Seller
owns and operates Bell Plaza Pharmacy, located at 6339 S. Atlantic Avenue,
Bell, California 90201(“Bell”).

          B.          Bell
owns certain assets (collectively, the “Assets”) consisting of the: (a) Seller’s
inventory of stock, and (b) all of the furniture, fixtures, equipment, computer
hardware and software. Assets do not include Seller’s accounts receivable, cash
on hand and in banks or corporate books and records.

          C.          Seller
desires to sell, assign and transfer to Buyer and Buyer desires to purchase and
acquire the Assets from Seller.

AGREEMENT

          NOW,
THEREFORE, in consideration of the terms, covenants,
and conditions hereinafter set forth, and other valuable consideration, the
receipt and sufficiency of which is hereby acknowledged, the parties hereto
agree as follows:

          1.          Purchase and Sale of Assets.  

                       Subject
to the terms and conditions of this Agreement, on the Closing Date (as defined
in Section 4 herein), Seller does hereby agree to sell, convey, assign,
transfer, and deliver to Buyer, and Buyer agrees to purchase from Seller the
Assets.

          2.          Consideration.  

                        In
consideration for the sale and transfer of the Assets from Seller to Buyer,
Buyer shall assume responsibility to pay to Seller’s creditors the maximum sum
of Twenty Thousand Dollars ($20,000) (“the Consideration”). 

	
  

 	
  

 
	
  

 	
                     a.          $15,000
 of the Consideration shall be applied by Buyer to payment of debts to
 Seller’s merchandise vendors (“Vendor Debts”).

 
	
  

 	
  

 
	
  

 	
                     b.          The
 remaining $5,000 of the Consideration shall be held by Buyer for a period of
 eighteen (18) months from and after the Closing Date, in an interest bearing
 account, during which it is to be applied to the payment of Seller’s debts
 other than Vendor Debts. Any
 Consideration not expended for the payment of Seller’s debts, after 18
 months, shall be released to Seller, together with any interest which may
 have accrued.

 

	
  

 	
  

 
	
  

 	
 3.          Non-Assumption
of Liabilities.  

 
	
  

 	
  

 
	
  

 	
              It
 is expressly agreed that, other than Buyer’s responsibility to pay up to a
 maximum of Twenty Thousand Dollars .to creditors of Seller, Buyer is not
 assuming any further responsibility for Seller’s or Bell’s debts, accounts
 payable, taxes, penalties, obligations, or liabilities of or associated with
 the Assets or arising out of or relating to events occurring Prior to the
 Closing Date, except for sales tax relating to the purchase and sale of such
 of the Assets as may be required by the California State Board of
 Equalization.

 
	
  

 	
  

 
	
  

 	
 3.         Closing Date.  

 

                       Subject
to the satisfaction or waiver of all conditions precedent as set forth in this
Agreement, the consummation of the purchase and sale of the Assets and all
transactions contemplated herein shall occur on September 2, 2009 (the “Closing Date”).

          4.          Conditions Precedent to Closing.

                       The
closing, and Buyer’s duty to perform, shall be contingent upon satisfaction or
Buyer’s written waiver of the following:

                              a.          Buyer
shall obtain a temporary permit from the California State Board of Pharmacy (“Temporary
Permit”). Buyer agrees to
use commercially reasonable diligent efforts to obtain the Temporary Permit,
and Seller shall reasonably assist Buyer in obtaining same.

          5.          Bill of Sale.

                       On
the Closing Date, Seller shall deliver to Buyer a duly executed Bill of Sale,
in the form attached hereto as Exhibit “A”.

          6.          Representations and Warranties of Seller.

                      As
of the date of this Agreement and as of the Closing Date, Seller represents and
warrants to Buyer the following, the truth and accuracy of each of which shall
constitute a condition precedent to the obligations of Buyer and which shall
survive the Closing Date:

                      a.          Authority.
Seller is a corporation, duly organized, validly
existing, and in good standing under the laws of the State of California, and
has full authority to execute and deliver this Agreement and consummate the
transactions contemplated hereby, and when executed this Agreement will be a
legal, valid and binding obligation of Seller, enforceable in accordance with
its terms.

                      b.          Title to
Assets. On the Closing Date, Seller shall convey and transfer to
Buyer, good, complete and marketable title to all of the Assets, free and clear
of restrictions or conditions of transfer or assignment, and free and clear of
all defects of title, claims, security interests or restrictions.

                      c.          Legal
Actions / Adverse Audits. There are no actions, suits or
proceedings pending or threatened against Seller which, individually or in the
aggregate, could have a material adverse effect on any of the Assets or the
transactions contemplated herein, whether at law or in equity. Seller is not in
default with respect to any order, writ, injunction or decree of any federal,
state or local court, department, agency or instrumentality, or of any
arbitrator, which is directed against it, and is not in violation of any
applicable federal, state or local statute, law or regulation which would have
a material adverse effect on the transactions contemplated herein or on the
Assets. Seller has not been the subject of any materially adverse audit
conducted by any third party claims payer within the twelve (12) month period
immediately preceding the Closing Date.

                      d.          Condition
of Assets. All of the
Assets are in good condition and/or repair except for normal wear and tear, and
are fit for the purposes for which they are being used.

          7.          Representations and Warranties of Buyer.

                      As
of the date of this Agreement and as of the Closing Date, Buyer represents and
warrants to Seller the following, the truth and accuracy of each of which shall
constitute a condition precedent to the obligations of Seller and which shall
survive the Closing Date:

                      a.          Authority.
Buyer is corporation, duly organized, validly existing, and in good standing
under the laws of the State of California, and has full power and authority to
execute and deliver this Agreement and consummate the transactions contemplated
hereby, and when executed this Agreement will be a legal, valid and binding
obligation of Buyer, enforceable in accordance with its terms.

                      b.          Permits
and Licenses. Buyer
understands and acknowledges that Buyer will be required to obtain all
necessary permits and licenses to operate any pharmaceutical business in its
own name, from the appropriate regulatory agencies, and that Seller shall not
deliver any such permits or licenses.

                      c.          Retention
of Records. Buyer agrees to preserve all records of acquisition
and disposition of dangerous drugs, and provide Seller with reasonable access thereto
and permit Seller to make copies thereof during normal business hours, for a
period of not less than three (3) years following the Closing Date.

          8.         Indemnification

                      a.           Buyer
shall indemnify, defend and hold harmless Seller, its officers, directors,
shareholders, agents, successors, and assigns from and against any and all
claims, demands, losses, liabilities, costs, expenses, obligations and damages,
including, without limitation, debts and interest, penalties and reasonable
attorneys’ fees, suffered or incurred by Seller which arise, result from or
relate to any material breach of or failure by Buyer to perform any of its
covenants or agreements in this Agreement, or from any material inaccuracy of any
representation or warranty of Buyer in this Agreement, or which arise, result
from or relate to any liability or obligation of Buyer arising out of the
conduct and operation of Buyer’s 

pharmaceutical company
before or after the Closing Date, which are not specifically assumed by
Seller hereunder. 

                      b.          Seller
shall indemnify, defend and hold harmless Buyer, its officers, directors,
shareholders, agents, successors, and assigns from and against any and all
claims demands, losses, liabilities, costs, expenses, obligations and damages,
including, without limitation, debts and interest, penalties and reasonable
attorneys’ fees, suffered or incurred by Buyer which arise, aresult form or
relate to any material breach of or failure by Seller to perform any of its
covenants or agreements in this Agreement, or from any material inaccuracy of
any representation or warranty of Seller in this Agreement, or which arise,
result from or relate to any liability or obligation of Seller arising out of
the conduct and operation of Seller’s Pharmaceutical companies, before or after
the Closing date, which are not specifically assumed by Buyer hereunder.

          9.          General
Provisions.

                              a.          
Time.
Time is of the essence to the performance of the parties under this Agreement.

                              b.          Sales Tax.
Buyer shall be responsible for payment of all sales and use taxes arising out
of the transfer of the Assets, if any.

                              c.          Expenses.
Each of the parties shall pay all costs and expenses incurred or to be incurred
by it in negotiating and preparing this Agreement and in closing and carrying
out the transactions contemplated by this Agreement. Property taxes and
insurance (if assumed by Buyer, at its option) will be prorated as of the
Closing Date.

                              d.          Notices.
All notices, statements or demands shall be in writing and shall be served in
person, by facsimile, by express mail, by certified mail or by private
overnight delivery. Service shall be deemed conclusively made (a) at the time
of service, if personally served or transmitted by facsimile, (b) twenty-four
(24) hours after deposit in the United States mail, properly addressed and
postage prepaid, if served by express mail, or (c) five (5) days after deposit
in the United States mail, properly addressed and postage prepaid, return
receipt requested, if served by certified mail.

	
  

 	
  

 	
  

 	
  

 
	
  

 	
 Any notice
 to Seller shall be given to:

 	
  

 	
 Any notice
 to Buyer shall be given to:

 
	
  

 	
  

 	
  

 	
  

 
	
  

 	
 JORNIK, INC.

 	
  

 	
 ES RX, INC.

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	

 	
  

 	
  

 	

 	
  

 
	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
  

 	

 	
  

 	
  

 	

 	
  

 
	
  

 	
 Attn: Ivan
 Manes

 	
  

 	
 Attn: Aaron
 Crowley

 

                    Any
party may, by virtue of written notice in compliance with this paragraph, alter
or change the address or the identity of the person to whom any notice or copy
thereof is to be sent.

	
  

 	
  

 
	
  

 	
                     e.          Waivers.
 A waiver by any party of any of the terms and conditions of this Agreement in
 any one instance shall not be deemed or construed to be a waiver of 

 

	
  

 	
  

 
	
  

 	
 such term or condition for the future, or of any subsequent breach
 thereof, nor shall it be deemed a waiver of performance of any other
 obligation hereunder.

 
	
  

 	
  

 
	
  

 	
                     f.          Disputes.
 In the event a dispute shall arise between the parties, whether based on
 contract, tort, statute or other legal theory (including without limitation
 any claim of fraud or misrepresentation), arising out of or related to this
 Agreement, resulting in litigation, in addition to such other relief as may
 be awarded by the courts, the prevailing party or parties shall be entitled
 to recover reasonable attorneys’ fees, expenses and costs.

 
	
  

 	
  

 
	
  

 	
                     g.          Binding
 Effect. This Agreement shall be binding upon and inure to the
 benefit of the successors and assignees of the parties.

 
	
  

 	
  

 
	
  

 	
                     h.          Headings.
 The subject headings of the paragraphs and subparagraphs of this Agreement
 are for convenience only and shall not in any way affect the construction or
 interpretation of any provision of this Agreement.

 
	
  

 	
  

 
	
  

 	
                     i.          Entire
 Agreement. This Agreement, together with its Exhibits, and
 escrow instructions prepared by the Escrow Agent, contain the entire
 understanding of the parties hereto relating to the subject matter hereof and
 supersedes all prior and collateral agreements, understandings, statements
 and negotiations of the parties. Each party acknowledges that no
 representations, inducements, promises, or agreements, oral or written, with
 reference to the subject matter hereof have been made other than as expressly
 set forth herein.

 
	
  

 	
  

 
	
  

 	
                     j.          Severability.
 If any provision of this Agreement, as applied to any party or to any
 circumstance, shall be found by a court of competent jurisdiction to be void,
 invalid or unenforceable, the same shall in no way affect any other provision
 of this Agreement, the application of any such provision in any other
 circumstance, or the validity or enforceability of this Agreement.

 
	
  

 	
  

 
	
  

 	
                     k.          Governing
 Law/Interpretation. This Agreement shall be governed by,
 construed in accordance with and enforced under the laws of the State of
 California. Words used herein, regardless of the number and gender
 specifically used, shall be deemed and construed to include any other number,
 singular or plural, and any other gender, masculine, feminine or neuter, as
 the context requires. 

 

               IN
WITNESS WHEREOF, the parties hereto have duly executed this Agreement as of the
date first above written.

	
  

 	
  

 	
  

 	
  

 	
  

 	
  

 
	
 Seller:

 	
 Buyer:

 
	
  

 	
  

 
	
 JORNIK, INC.

 	
 ES RX, INC.

 
	
  

 	
  

 
	
 By: 

 	
 /s/ Ivan
 Manes

 	
  

 	
 By: 

 	
 /s/ Aaron
 Crowley

 	
  

 
	
 

 	

	
  

 	
 

 	

	
  

 
	
  

 	
 Ivan Manes,
 its President

 	
  

 	
 Aaron
 Crowley, its President

 

Exhibit “A”

Bill
of Sale

          This Bill
of Sale is made, executed and effective as of the 2nd day of
September, 2009, by JORNIK, Inc. (“Seller”) to ES RX, Inc. (“Buyer”). Unless
otherwise defined herein, all capitalized terms used in this Bill of Sale are
defined in the Purchase and Sale Agreement and Escrow Instructions, dated
September 2, 2009, by and between Seller and Buyer (the “Agreement”). This Bill
of Sale is being executed and delivered pursuant to, and in accordance with,
Paragraph 6 of the Agreement.

          Seller
hereby conveys, grants, bargains, sells, transfers, sets over, assigns,
delivers and confirms unto Buyer, its successors and assigns forever, all
right, title and interest of Seller in and to the Assets as set forth in, and
subject to the terms of, the Agreement; to have and to hold all of the Assets,
unto Buyer, its successors and assigns, to its own use.

          Seller
further covenants and agrees that it will do, execute and deliver, or will
cause to be done, executed and delivered, all such further acts, transfers,
assignments and conveyances, confirmations, powers of attorney, assurances and
consents, for the better assuring, conveying and confirming unto Buyer of all
the right, title and interest of Seller in and to the Assets, as Buyer shall
reasonably require.

          IN
WITNESS WHEREOF, Seller has executed this Bill of
Sale.

	
  

 	
  

 	
  

 	
  

 
	
  

 	
 Jornik,
 Inc..

 
	
  

 	
  

 	
  

 
	
  

 	
 By: 

 	
 /s/ Ivan
 Manes 

 	
  

 
	
  

 	
  

 	

	
  

 
	
  

 	
  

 	
 Ivan Manes,
 its Presidentex10-1.htm

 

LICENSE AGREEMENT

 

THIS AGREEMENT is dated effective September 2nd , 2009. (the “Effective Date”)

 

BETWEEN:

 

    0798465 B.C. LTD., a corporation incorporated under the laws of British Columbia, with a registered office located at Suite 235, 550 Sixth
Street, New Westminster, British Columbia, V3L 3B7

            (the “Licensor")

 

AND:

 

    MANTRA ENERGY ALTERNATIVES LTD.., a corporation incorporated under the laws of British Columbia, having an office at Suite 1205, 207 West Hastings Street, Vancouver, British Columbia V6B 1H7

            (the "Licensee")

 

WHEREAS:

 

A. The Licensor is the owner by assignment of all right, title and interest in and to the Mixed Reactant Flow-By Fuel Cell (“MRFBFC”) technology developed by Prof. Colin Oloman in the U.B.C.
Department of Chemical and Biological Engineering, as described and claimed in a PCT International Patent Application (serial number not yet assigned) filed on 7 August 2009, naming Colin Oloman as inventor, and entitled “Mixed Reactant Flow-By Fuel Cell” (the “Technology”);

 

B. It is the Licensor’s objective to exploit the Technology for its benefit by licensing the Technology to the Licensee; and,

 

C. The parties have agreed to enter into this Agreement on the terms and conditions set out herein.

 

 

1

 

 

NOW THEREFORE, in consideration of the premises and mutual covenants hereinafter set forth and other good and valuable consideration (the receipt and sufficiency of which is hereby acknowledged), the parties covenant and agree as follows:

 

	
1.0
	
DEFINITIONS

 

	
1.1
	
Unless specifically set forth to the contrary herein, the following terms will have the respective meanings set forth below:

 

	
(a)  
	
“Agreement” means this License Agreement, including any recitals hereto and any Schedules annexed hereto, as the same may be amended from time to time in accordance with the provisions hereof; “hereof”, “hereto” and “hereunder” and similar expressions mean and
refer to this Agreement and not to any particular article or section.

 

	
(b)  
	
"Confidential Information" means all information in written or other recorded form, including paper and electronic forms, that is disclosed by a disclosing party (the "Discloser") to a recipient (the "Recipient")
and that is marked or otherwise designated  as “Confidential”, except that Confidential Information does not include information:

 

	
(i)  
	
possessed by the Recipient prior to receipt from the Discloser, other than through prior disclosure by the Discloser, as evidenced by the Recipient's business records;

 

	
(ii)  
	
published or available to the general public otherwise than through a breach of this Agreement;

 

	
(iii)  
	
obtained by the Recipient from a third party with a valid right to disclose it, provided that the third party is not under a confidentiality obligation to the Discloser; or,

 

	
(iv)  
	
independently developed by employees, agents or consultants of the Recipient who had no knowledge of or access to the Discloser's information as evidenced by the Recipient's business records.

 

	
(c)  
	
 “Gross Revenue” means: (a) the invoiced amount actually paid to the Licensee for Products, less any standard trade allowances or discounts actually deducted; and (b) the fair market value of any shares or other securities, and all other consideration directly or indirectly collected or received,
whether by way of cash, credit or other value received by the Licensee from any source arising as a result or consequence of the exploitation by the Licensee of the Technology or Improvements, or from the marketing, manufacturing, sale or distribution of the Products.

 

	
(d)  
	
 “Improvements" means, collectively, all Licensee Improvements, Licsensor improvements, and Joint Improvements.

 

	
(e)  
	
“IP Rights” means all intellectual property rights relating to the Technology and Improvements, and subject to protection by intellectual property laws in any country of the world, arising under statutory or common law, contract or otherwise, and whether or not perfected, including without limitation,
all:

 

	
(i)  
	
Patent Rights;

 

	
(ii)  
	
rights associated with works of authorship, including without limitation copyrights, moral rights, copyright applications, copyright registrations;

 

	
(iii)  
	
rights associated with trademarks, service marks, trade names, logos, trade dress, goodwill and the applications for registration and registrations thereof;

 

 

2

 

 

 

	
(iv)  
	
rights relating to the protection of trade secrets, know-how and confidential information, including, but not limited to, formulae, procedures, protocols, techniques and results of experimentation and testing, which are necessary or useful to make, have made, use, develop, sell, import or seek regulatory approval to market a composition, or to practice any method
or process, at any time claimed or disclosed or disclosed in any issued patent or pending patent application;

 

	
(v)  
	
rights analogous to those set forth in this definition; and,

 

	
(vi)  
	
any and all other proprietary rights relating to intangible property now existing, hereafter filed, issued or acquired.

 

	
(f)  
	
“Joint Improvements” means all improvements, variations, updates, modifications, and enhancements relating to the Technology made and/or conceived jointly by the Licensee and by the Licensor at any time after the Effective Date, and which cannot be legally used or practiced without infringing the
IP Rights to the Technology licensed under this Agreement.

 

	
(g)  
	
“License” means the license granted by the Licensor to the Licensee pursuant to this Agreement.

 

	
(h)  
	
“Licensee Improvements" means all improvements, variations, updates, modifications, and enhancements relating to the Technology made and/or conceived solely by the Licensee (including employees, agents or consultants of the Licensee) at any time after the Effective Date, and which cannot be legally used
or practiced without infringing the IP Rights to the Technology licensed under this Agreement.

 

	
(i)  
	
“Licensor Improvements" means all improvements, variations, updates, modifications, and enhancements relating to the Technology made and/or conceived solely by the Licensor (including employees, agents or consultants of the Licensor) at any time after the Effective Date, and which cannot be legally used
or practiced without infringing the IP Rights to the Technology licensed under this Agreement.

 

	
(j)  
	
“MRFBFC” is defined in Recital A.

 

	
(k)  
	
“Patent Rights” means collectively the rights in and to any and all inventions relating to the Technology as disclosed and claimed in the Patents, and all counterparts, continuations, divisionals, continuing prosecution applications, requests for continuing prosecution, extensions, term restorations,
renewals, reissues, re-examinations, or substitutions thereof, and all corresponding foreign patent applications, supplementary protection certificates, or other administrative protections, and any foreign counterpart patents resulting therefrom.

 

	
(l)  
	
“Patents” means the patent application described in Recital A, including any national or regional patents or patent applications derived therefrom, and any patents issued and patent applications filed in accordance with the provisions of Part 5 of this Agreement.

 

	
(m)  
	
“Product” and “Products” means any product manufactured or service provided that if made, used, sold, offered for sale or imported absent the License granted hereunder would infringe either a Valid Claim or other IP Rights to the
Technology or Improvements granted hereunder.

 

	
(n)  
	
“Royalty” is defined in Part 4 of this Agreement.

 

	
(o)  
	
“Sublicense” means the sublicense to be granted by the Licensee to any sublicense subsequent to this Agreement, as further described in Part 3 hereof.

 

	
(p)  
	
“Technology” is defined in Recital A.

 

	
(q)  
	
“Valid Claim” means either (a) a claim of an issued and unexpired patent included within the Patents, which has not been held permanently revoked, unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, un-appealable or un-appealed within the time
allowed for appeal, and which has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, or (b) a claim of a pending patent application included within the Patents, which claim was filed in good faith and has not been abandoned or finally disallowed without the possibility of appeal or re-filing of such application.

 

 

3

 

 

 

	
2.0
	
PROPERTY RIGHTS IN AND TO THE TECHNOLOGY

 

	
2.1
	
As between the Licensor and the Licensee, the Licensee acknowledges and agrees that the Licensor owns all right, title and interest in and to the Technology and in and to any Licensor Improvements

 

	
2.2
	
The Licensee will not contest the validity or scope of any patents or patent applications that may be filed or issued in relation to the Technology or to the Licensor Improvements, and will, at the request of the Licensor, sign all documents as may be required to ensure that ownership of the Technology and all Licensor Improvements
remains solely with the Licensor.

 

	
2.3
	
The Licensor acknowledges and agrees that the Licensee owns all right, title and interest to any Licensee Improvements.  Except as explicitly set forth in this Agreement, the Licensee is under no restriction or obligation to the Licensor with respect to the Licensee Improvements.

 

	
2.4
	
All right, title and interest in any Joint Improvements shall be jointly owned by the Licensor and the Licensee.  On the last business day of June and December of each year during the term of this Agreement, the Licensee will give notice to the Licensor of the details of any Licensee Improvements or Joint Improvements which
the Licensee has developed and/or acquired during the previous six month period.

 

	
3.0
	
GRANT OF LICENSE

 

	
3.1
	
Subject to and in accordance with the terms and conditions set out in this Agreement, the Licensor grants to the Licensee a worldwide, exclusive, royalty-bearing License in all fields of use (including, without limitation, the exclusive right to grant sublicenses in accordance Part 3 hereof) under its IP Rights to the Technology and
any Improvements, to use, research, discover, develop, make, manufacture, have made, distribute, offer to sell, provide, import and sell Products for a term as defined in Sections 10 and 11 of this Agreement.

 

	
3.2
	
The license granted under this Agreement is granted only to the Licensee and not to any affiliated companies thereof, except for wholly owned subsidiaries of the Licensee, wherein the Licensee will be fully liable for and shall guarantee the performance of such wholly owned subsidiary under the terms and conditions of this Agreement;

 

	
3.3
	
The Licensee acknowledges and agrees that U.B.C. may use the Technology without charge in perpetuity in any manner at all for research, scholarly publication, educational and all other non-commercial uses;

 

	
3.4
	
The Licensee will not grant Sublicenses of the Technology to third parties without the prior written consent of the Licensor.  Each Sublicense granted by the Licensee hereunder will be subject to and subordinate to the terms and conditions of this Agreement, and will contain terms and conditions consistent with those in this
Agreement.  Notwithstanding the terms of the Sublicense, the obligations and liabilities of the Licensee and any sublicense will be joint and several, and the Licensor will not be obliged to seek recourse against any sublicense before enforcing its rights against the Licensee if any action of any sublicense constitutes a breach of this Agreement.

 

 

4

 

 

 

	
3.5
	
In the event that this Agreement terminates pursuant to Section 9 hereof, any Sublicense granted under the terms and conditions hereof shall, upon the written request of the sublicensee, become a direct license between the Licensor and that sublicensee so long as: (a) the Sublicense does not impose obligations on the Licensor beyond
those set forth in this Agreement, and (b) the sublicensee is not in breach of its Sublicense agreement or, mutatis mutandis, the terms of this Agreement.

 

	
4.0
	
LICENSE FEES AND ROYALTIES

 

	
4.1
	
As a condition of the Licensor granting this License, the Licensee agrees to pay to the Licensor the following license fees:

 

	
(a)  
	
an initial license fee of CAD $10,000 (the "Initial License Fee"), payable in two installments: $5,000 upon execution of this Agreement, and $5,000 within 30 days of the Effective Date of this Agreement;

 

	
(b)  
	
a further license fee of CAD $15,000, to be paid within 90 days of the Effective Date of this Agreement, in partial reimbursement of fees incurred by the Licensor in relation to the preparation, filing and maintenance of patents for the Technology; and,

 

	
(c)  
	
an annual license fee, payable annually on the anniversary of the Effective Date of this Agreement, according to the following schedule:

 

 

	 First Anniversary     	=           CAD $10,000
	 Second Anniversary  	=           CAD $20,000
	 Third Anniversary 	=           CAD $30,000
	 Fourth Anniversary 	=           CAD $40,000
	 Fifth and each Successive Anniversary	=           CAD $50,000

     

 

	
4.2
	
The Licensee will also pay to the Licensor a royalty calculated as 2% of the Gross Revenue, and 15% of any and all consideration directly or indirectly received by the Licensee from the grant of any sublicense rights (the Royalty).  The Royalty will be calculated quarterly commencing on the Effective Date of this Agreement, and
paid within 30 days of each period end.

 

	
4.3
	
The Licensee will pay interest on all amounts due and owing to the Licensor under this Agreement but not paid by the Licensee on the due date, at a rate of 1% per month.  The interest will accrue on the balance of unpaid amounts from time to time outstanding, from the date on which portions of the amounts become due and owing
until payment in full.

 

	
4.4
	
The Licensee agrees that for itself and for each sublicensee, that they shall agree to keep clear, accurate and complete records for a period of at least three (3) years (or such longer period as may correspond to the Licensee’s internal records retention policy) for each reporting period in which revenue occurs, showing the manufacturing,
sales, use and other disposition of Product in sufficient detail to enable the royalties payable hereunder to be determined, and further agrees to permit its books and records to be examined by an independent accounting firm selected by the Licensor and reasonably satisfactory to the Licensee, from time-to-time to the extent necessary, during normal business hours and upon reasonable notice, but not more than once a year.  Such examination is to be made at the expense of the Licensor, except in the
event that the results of the audit reveal that the Licensee underpaid the Licensor by five percent (5%) or more, then the audit fees shall be paid by the Licensee.  Any such discrepancies will be promptly corrected by a payment or refund, as appropriate.

 

 

5

 

 

	
5.0
	
PATENTS

 

	
5.1
	
In addition to the timely payment of Royalty and the license fees pursuant to Part 4 hereof, the Licensee will be responsible for the timely payment of all future costs, commencing upon the Effective Date and continuing for a period as defined in Section 10 hereof, associated with the drafting, filing, prosecution and maintenance, all
under the direction and control of the Licensor, of any patents or patent applications that describe or claim the Technology, or any new and useful art, process, machine, manufacture or composition of matter arising out of any Licensor Improvements or Joint Improvements licensed under this Agreement and identified by the Licensor as potentially patentable.

 

	
5.2
	
The Licensee will, from time to time upon the Licensor’s request, pay to the Licensor a reasonable payment as an advance against expected patent expenses. Within 30 days of presentation of receipts and/or invoices by the Licensor to the Licensee, the Licensee will reimburse the Licensor for the balance of all costs incurred to
date regarding any Patents or applications relating to the Technology and any Licensor Improvements or Joint Improvements licensed under this Agreement.

 

	
5.3
	
The Licensee will ensure proper patent marking for all uses of the Technology and any Licensor or Joint Improvements licensed under this Agreement. Nothing in this agreement governs or prohibits the Licensee from applying for and obtaining patents in respect of Licensee Improvements.

 

	
6.0
	
REPRESENTATIONS AND WARRANTIES

 

	
6.1
	
Representations and Warranties of the Licensor.  As a material inducement to the Licensee entering into and performing this Agreement, the Licensor represents, warrants and covenants that:

 

	
(a)  
	
The Licensor is a corporation duly organized, validly existing and in good standing under the laws of its province of incorporation, and has full corporate power and authority to conduct its business as it is now being conducted, to own and use its assets, to enter into, deliver and perform this Agreement and any agreement or instrument executed in connection herewith
or delivered pursuant hereto and to consummate the transactions contemplated hereby.

 

	
(b)  
	
The Licensor’s execution, delivery and performance of this Agreement and all agreements and instruments executed in connection herewith or delivered pursuant hereto have been duly authorized by all requisite corporate action by the Licensor.  This Agreement will be duly executed and delivered by the Licensor, and this Agreement constitutes the Licensor’s
legal, valid and binding obligation and is enforceable against the Licensor in accordance with its terms.

 

	
(c)  
	
The execution, delivery and performance of this Agreement does not and will not:

 

	
(i)  
	
contravene, conflict with, or result in a violation of any provision of the Articles of Incorporation, Bylaws or other governing document of the Licensor,

 

	
(ii)  
	
contravene or conflict with, or result in a breach of, any agreement, contract or arrangement between the Licensor and any other person or which would materially adversely affect the transactions contemplated hereby,

 

	
(iii)  
	
result in the violation by the Licensor of any law, rule or regulation applicable to the Licensor or the Technology, or

 

	
(iv)  
	
require the approval, consent or authorization of any federal, state, provincial or local governmental authority or any other person.

 

	
(d)  
	
The Licensor owns all right, title and interest in the Technology.

 

 

6

 

 

 

	
(e)  
	
As of the date hereof, there is no pending, or to the knowledge of the Licensor, threatened (whether written, oral or otherwise) claim, action or proceeding against the Licensor contesting or questioning the validity of the Technology, or the right of the Licensor to own, sell, license of use the Technology, or asserting that any other person has any claim of legal
or beneficial ownership with respect thereto.

 

	
(f)  
	
The Licensor has not provided and will not provide any party or person other than the Licensee with any rights in connection with or arising out of the Technology.

 

	
(g)  
	
The Licensor has the right to grant to the Licensee a license to use the Technology and all other rights explicitly provided for in this Agreement, and the Licensor has not entered into any arrangement or understanding or shall do any act which might in any way inhibit, restrict or impair the free and unrestricted exercise of the rights by the Licensee or which
conflicts with the Licensor’s obligations under this Agreement.

 

	
(h)  
	
The Licensor has not employed or made any agreement with any broker, finder or similar agent or any person or firm which will result in the obligation of the Licensor to pay any finder’s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby.

 

	
6.2
	
Representations and Warranties of the Licensee.  As a material inducement to the Licensor entering into and performing this Agreement, the Licensee represents, warrants and covenants that:

 

	
(a)  
	
The Licensee is a corporation duly organized, validly existing and in good standing under the laws of its province of incorporation, and has full corporate power and authority to conduct its business as it is now being conducted, to own and use its assets, to enter into, deliver and perform this Agreement and any agreement or instrument executed in connection herewith
or delivered pursuant hereto and to consummate the transactions contemplated hereby.

 

	
(b)  
	
The Licensee’s execution, delivery and performance of this Agreement and all agreements and instruments executed in connection herewith or delivered pursuant hereto have been duly authorized by all requisite corporate action by the Licensee.  This Agreement will be duly executed and delivered by the Licensee, and this Agreement constitutes the Licensee’s
legal, valid and binding obligation and is enforceable against the Licensee in accordance with its terms.

 

	
(c)  
	
The execution, delivery and performance of this Agreement does not and will not:

 

	
(i)  
	
contravene, conflict with, or result in a violation of any provision of the Articles of Incorporation, Bylaws or other governing document of the Licensee,

 

	
(ii)  
	
contravene or conflict with, or result in a breach of, any agreement, contract or arrangement between the Licensee and any other person,

 

	
(iii)  
	
result in the violation by the Licensee of any law, rule or regulation applicable to the Licensee, or

 

	
(iv)  
	
require the approval, consent or authorization of any federal, state, provincial or local governmental authority or any other person.

 

	
(d)  
	
The Licensee has not employed or made any agreement with any broker, finder or similar agent or any Person or firm which will result in the obligation of The Licensee to pay any finder’s fee, brokerage fees or commission or similar payment in connection with the transactions contemplated hereby.

 

 

7

 

 

 

	
7.0
	
INDEMNITY AND LIMITATION OF LIABILITY

 

	
7.1
	
Nothing in this Agreement shall be construed as: a) a warranty or representation by the Licensor as to the validity, enforceability or scope of any Patent; b) a warranty or representation that anything made, used, sold, or otherwise disposed of pursuant to this Agreement is or will be free from infringement of patents or other intangible
rights of third parties; or a warranty or representation that the practice (or making, using, selling, offering, importing or transferring Products licensed hereunder) under the IP Rights is or will be free from infringement of patents of third parties; c) an obligation by the Licensor to file any patent application, secure any patent, or maintain any patent in force; d) any obligations of the Licensor to prosecute, enforce or sublicense its IP Rights to (or against) third party infringers; e) except as expressly
set forth herein, conferring upon the Licensee the right to use in advertising, publicity or otherwise, in any form, the name of, or any trademark or trade name of, the Licensor or any of its affiliates; f) granting by implication, estoppel, or otherwise, any license, immunity or rights under the IP Rights other intangible rights of the Licensor other than the express licenses granted under the Technology and Improvements pursuant to Part 3;  or g) creating any agency, partnership, joint venture or
similar relationship between the Licensor and the Licensee.

 

	
7.2
	
EXCEPT AS EXPRESSLY STATED HEREIN, THE LICENSOR MAKES NO EXPRESS OR IMPLIED WARRANTIES OF ANY KIND (INCLUDING, WITHOUT LIMITATION, ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NONINFRINGEMENT) WITH RESPECT TO THE TECHNOLOGY OR IMPROVEMENTS, THE PRACTICE OF THE LICENSE HEREUNDER OR THE MAKING, USING OR SELLING
OF PRODUCTS LICENSED HEREUNDER.  IN NO EVENT SHALL THE LICENSOR BE LIABLE FOR ANY SPECIAL, PUNITIVE, INCIDENTAL OR CONSEQUENTIAL DAMAGES (INCLUDING, WITHOUT LIMITATION LOST PROFITS).

 

	
7.3
	
The Licensee and any sublicensee shall assume full responsibility for its or their operation under the Patents under which rights are granted in this Agreement, the manufacture of any Products and the use thereof, and shall defend, indemnify and hold the Licensor harmless from and against all liability, demands, damages, expenses (including
attorneys' fees) and losses for death, personal injury, illness, property damage or any other injury or damage, including any damages or expenses arising in connection with regulatory action, in view of the use by the Licensee and any sublicensee, its officers, directors, agents and employees of the Technology and Improvements and the manufacture and use of Products except that the Licensee and any sub-licensee shall not be liable to the Licensor for injury or damage arising solely to the extent of the Licensor's
negligence.

 

	
8.0
	
PERFORMANCE REQUIREMENTS

 

	
8.1
	
The Licensee represents and warrants to the Licensor that it will, throughout the term of this Agreement, use its best efforts to promote, market and sell the Products and exploit the Technology and to meet or cause to be met the market demand for the Products and the use of the Technology; and,

 

 

 

8

 

 

	
8.2
	
The Licensee will:

 

	
(a)  
	
complete a Development Plan describing the plans for commercializing the Technology within 12 months of executing this Agreement.  The Development Plan will be prepared in accordance with generally accepted business practices and will be updated from time to time, but in no event less than once every calendar year.  Copies of all updates of this
plan will be provided to the Licensor in a timely manner, an in any event within 30 days of the completion of the Development Plan.

 

	
(b)  
	
Within 2 years of the execution of this Agreement invest a minimum of $250,000 in research and development directly associated with the Technology.

 

	
(c)  
	
Within 12 months of the execution of this Agreement, demonstrate one of:

	
i.  
	
A single cell incorporating the Technology with a power output at least 4 W and superficial power density at least 500 W/m2; OR

	
ii.  
	
A single cell incorporating the Technology with superficial power density at least 500 W/m2 with corresponding voltage at least 0.5 Volt/cell

AND demonstrate one of:

 

	
i.  
	
A multicell stack incorporating the Technology with total power output of at least 10 W and volumetric power density of at least 500 W/L; OR

	
ii.  
	
A multicell stack incorporating the Technology with power output at least 1 W at 5 Volts and volumetric power density at least 250 W/L.

 

	
9.0
	
USE OF THE LICENSOR’S OR OF UBC’S NAME

 

	
9.1
	
The Licensee will not use the make reference to the Licensor or its name in any advertising or publicity, without the prior written consent of the Licensor.  The Licensee will not use the UBC Trade-marks or make reference to UBC or its name in any advertising or publicity, without the prior written consent of UBC.  Without
limitation, the Licensee will not issue a press release regarding this Agreement, this Agreement or the Technology without first obtaining the Licensor’s written approval.  If the Licensee is required by law to act in breach of this Article, the Licensee will provide the Licensor with as much prior notice as reasonably possible.  The Licensor does agree that the Licensee will disseminate a press release which will contain the following text: “Mantra Venture Group Ltd. has entered
into negotiations for the acquisition of a formate fuel cell technology” AND/OR “Mantra Venture Group Ltd. has entered into negotiations for the acquisition of a novel mixed reactant fuel cell technology”.  Upon execution of this Agreement by both parties, the Licensee will, upon receiving consent from the Licensor (not to be unreasonably withheld), disclose the existence of this Agreement.

 

	
10.0
	
TERM OF LICENSE AGREEMENT

 

 

9

 

 

	
10.1
	
The term of this Agreement will start on the Effective date of this Agreement and end on:

 

	
(a)  
	
the day that is exactly 20 years later; or

 

	
(b)  
	
the expiry of the last patent licensed under this Agreement,

 

        whichever is last to occur, unless terminated earlier.

 

	
11.0
	
TERMINATION OF LICENCE AGREEMENT

 

	
11.1
	
This Agreement will terminate without notice to the Licensee if any proceeding under the Bankruptcy and Insolvency Act of Canada, or any other statute of similar purpose, is started by or against the Licensee.

 

	
11.2
	
The Licensor will have the option of terminating this Agreement immediately upon written notice to the Licensee if:

 

	
(a)  
	
The Licensee is in default of any material term in this Agreement;

 

	
(b)  
	
the Licensee becomes insolvent;

 

	
(c)  
	
any execution or other process of any court becomes enforceable against the Licensee with regard to the Technology, the rights under this Agreement or on any money due to the Licensor;

 

	
(d)  
	
any resolution is passed or order made or other steps taken for the winding up, liquidation or other termination of the existence of the Licensee; or

 

	
(e)  
	
the Technology becomes subject to any security interest, lien, charge or encumbrance in favour of any third party claiming through the Licensee.

 

	
(f)  
	
If any sublicensee of the Licensee is in breach of the sublicense with the Licensee and the Licensee has not either caused the sublicensee to cure such breach or terminated the sublicense within 30-days.

 

	
(g)  
	
if the Licensee, or any Affiliated Licensor is in breach of any other agreement between the Licensee or such Affiliated Licensor and the Licensor and the breach has not been cured within 30-days.

 

	
11.3
	
The right of the Licensor to terminate this Agreement as provided herein shall not be affected in any way by its waiver of, or failure to take action with respect to, any previous failure to perform hereunder.

 

 

10

 

 

	
11.4
	
Termination for any reason hereunder shall not affect any accrued rights or obligations of the parties arising in any manner under this Agreement as of the date of termination.  In any event, the indemnity obligations and any accrued payment obligations under Parts 7 and  4 shall survive any termination of this Agreement,
as will the obligation to preserve sub-licenses in section  3.5.

 

	
12.0
	
INSURANCE

 

	
12.1
	
During the term of this Agreement, the Licensee and any sublicensees will procure and maintain insurance (including public liability and commercial general liability insurance), as would be acquired by a reasonable and prudent businessperson carrying on a similar line of business, and such insurance will include the Licensor as an additional
insured.

 

	
13.0
	
GOVERNING LAW

 

	
13.1
	
This Agreement will be governed by, and will be construed in accordance with, the laws of British Columbia and the laws of Canada in force in that province, without regard to its conflict of law rules.  The parties agree that they will have attorned to the jurisdiction of the Supreme Court of British Columbia.  The
British Columbia Supreme Court will have exclusive jurisdiction over this Agreement.

 

	
14.0  
	
ASSIGNMENT

 

	
14.1
	
This Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either party by operation of law or otherwise, without the prior written consent of the other party; provided, however, that either party may, without the other party’s consent, assign this Agreement
and its rights and obligations hereunder in whole or in part to an affiliate upon notice to the other party.  Any attempted assignment not in accordance with this provision will be void.

 

	
15.0
	
SEVERABILITY

 

	
15.1
	
If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein will not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the
substantive rights of the parties.  The parties will in such an instance use their best efforts to replace the invalid, illegal or unenforceable provision(s) with valid, legal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.

 

	
16.0  
	
BINDING EFFECT

 

	
16.1
	
As of the Effective Date, this Agreement will be binding upon and inure to the benefit of the parties and their respective permitted successors and permitted assigns.

 

	
17.0
	
NO THIRD PARTY BENEFICIARIES

 

	
17.1
	
Except as expressly contemplated herein, no third party, including any employee of any party to this Agreement, will have or acquire any rights by reason of this Agreement.

 

 

11

 

 

 

	
18.0
	
ENTIRE AGREEMENT

 

	
18.1
	
This Agreement contains the entire understanding of the parties with respect to the subject matter hereof and the licenses granted hereunder, and supersedes all express or implied agreements or understandings, either oral or written, with regard to the subject matter hereof and
the licenses granted hereunder.  This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representatives of both parties hereto.

 

 

	
SIGNED FOR AND ON BEHALF of the LICENSOR 0798465 B.C. LTD

by its authorized signatories:

	 
	
Per: /s/ Colin Oloman

	
Authorized Signatory

	 
	Colin Oloman,  President
	
Name and Title

 

 

	
SIGNED FOR AND ON BEHALF of  the LICENSEE

MANTRA ENERGY ALTERNATIVES LTD.

by its authorized signatory:

	 
	
Per: /s/ Larry Kristof

	
Authorized Signatory

	 
	Larry Kristof  President, Chief Executive Officer
	Name and Title of Signatory
	 
	
Date: September 2, 2009

 

 

12

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00162-of-00352.parquet"}]]